DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2042
INDEX
Lice, 1818–1819
Lichen planus
cyclosporine for, 1821
dapsone for, 1823
photochemotherapy for, 1814
tacrolimus for, 1822
Lichen sclerosus, retinoids for, 1811
Licofelone, 941
Liddle syndrome, 692
LIDEX-E (fluocinonide cream), 1225t
LIDEX (fluocinonide), 1225t
Lidocaine, 841
as anesthetic, 572–573
antiarrhythmic use of, 824t, 827,
828, 835t, 841–842
dosage of, 835t
electrophysiological actions of, 829t
metabolism of, 128t
pharmacokinetics of, 835t, 841–842
polymorphisms and response to,
159t
Ligand-gated ion channels, 60
Ligandin, 136
Limbic system, 364
Limbus, 1774, 1776f
Lincosamides, 1534–1535
Lindane
adverse effects and side effects of,
1819
contraindications to, 1819
mechanism of action of, 1818
neurotoxicity, 1819
structure of, 1819
Linear IgA dermatosis, dapsone for,
1823
Linezolid, 1537–1538
pharmacokinetics of, 1857t
Linkage disequilibrium, 149
Linkage equilibrium, 149
Liothyronine sodium, 1143
Lipid-derived autocoids, 937
Lipid-lowering therapy
benefits of, 877
clinical trials of, 885
for diabetics, 891
limits for, 891
Lipid mediators, 389–390
Lipids, plasma, levels of, levels,
treatment based on, 886t
LIPITOR (atorvastatin), 897
Lipocortins, 941
Lipopeptides, 1542–1543
Lipoprotein(a), 879t, 884
niacin and, 900
Lipoprotein lipase (LPL), 881
Lipoproteins
ethanol and, 635–636
oxidation of, statins and, 895
plasma
bile acid sequestrants and, 899
characteristics of, 879t
fibric acid derivatives and, 902
metabolism, 878–884
metabolism of, 878–884
nicotinic acid and, 900
properties of, 878, 879t
β-Lipotropin (β-LPH), 1106t
γ-Lipotropin (γ-LPH), 1106t
Lipoxin receptors, 946
Lipoxins, 937
Lipoxygenase
pathways of arachidonic acid
metabolism, 940f
products of, 939–941
5-Lipoxygenase, 160t
5-Lipoxygenase activating protein
(FLAP), 939–941
Liraglutide, 1263–1264
Lisinopril
as antihypertensive agent, 774t,
784–785
clinical pharmacology of, 733
pharmacokinetics of, 1857t
structure of, 732f
therapeutic uses of, for heart failure,
797
Lissamine green, in ocular diagnosis,
1793
Listeria infection, 1487
Lithium
adverse effects of, 449–450
and antidiuretic response to
vasopressin, 708
for bipolar disorder, 447
drug interactions with, 448–449, 976
EKG effects of, 449
formulations, 450–451
in geriatric populations, 450
hypoglycemia and, 1248t
lactation and use of, 449–450
for mania, 445–447
mechanism of action, 445–446
overdose, 450
in pediatric populations, 450
pharmacokinetics of, 446–450,
1857t
in pregnancy, 449–450
renal effects of, 449
skin effects of, 449
therapeutic uses of, 447–451
Lithium (Cont.):
toxicity, 450
and vasopressin secretion, 704
LIVALO (pitavastatin), 897
Liver
ABC transporters in, 103–104,
105t–106t, 108
alpha adrenergic receptors in, 203t
in autonomic nervous system,
179t
barbiturates and, 472–473
bioavailability and disease in, 1802
in drug metabolism, 126
ethanol and, 638
function, heparin and, 859
halothane and, 547
isoflurane and, 548
transporters in, 108–111
vectorial transport in, 96, 96f,
108–109
Liver disease, obstructive, and
dyslipidemia, 890t
LIVOSTIN (levocabastine
hydrochloride), 922t
Lixivaptan, 717
LMWH. See Low molecular weight
heparin (LMWH)
Loading dose, 36–37
Loa loa, 1446–1447
LOCOID (cortisol butyrate), 1225t
LOCOID (hydrocortisone butyrate
cream), 1808t
Locust subesophageal ganglia peptide,
709t
Lodoxamide tromethamine, for
ophthalmic use, 1789
LOESTRIN 24, 1833–1834
LOESTRIN 1.5/30 (ethinyl
estradiol/norethindrone),
1835t
LOESTRIN 1/20 (ethinyl
estradiol/norethindrone),
1835t
LOESTRIN 24 (ethinyl
estradiol/norethindrone),
1836t
Lofepramine, potencies at human
transporters for monamine
neurotransmitters, 406t
LOFIBRA (fenofibrate), 903
Loiasis, 1446–1447
Long-loop negative feedback
mechanism, 723f, 724
Long QT syndrome, 820, 825
variant 3, 828